Key facts
- This page summarizes Eagle Equity Partners III, LLC's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 22 Sep 2021, 21:57.
Eagle Equity Partners III, LLC - 16 Sep 2021 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)
- Reporting relationship
- Director, *Director by Deputization, 10%+ Owner
- Issuer ticker
- DNA
- Reported as of
- 16 Sep 2021
- Net transaction value
- +$192,500,000
- Reporting owner signature
- /s/ Eli Baker
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Eagle Equity Partners III, LLC filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 22 Sep 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$192,500,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNA
transaction
Class A Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -11,534,052
- Change %
- -27%
- Price
- Shares after
- 31,590,948
- Date
- 16 Sep 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNA
transaction
Derivative
Class B Ordinary Shares
Options Exercise
- Transaction value
- Shares
- -43,125,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 43,125,000
- Exercise price
- Footnotes
- F1
DNA
transaction
Derivative
Private Placement Warrants
Award
- Transaction value
- $192,500,000
- Shares
- +19,250,000
- Change %
- Price
- $10.00*
- Shares after
- 19,250,000
- Date
- 16 Sep 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 19,250,000
- Exercise price
- $11.50
- Footnotes
- F2
DNA
transaction
Derivative
Private Placement Warrants
Disposed to Issuer
- Transaction value
- Shares
- -1,925,000
- Change %
- -10%
- Price
- Shares after
- 17,325,000
- Date
- 16 Sep 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 1,925,000
- Exercise price
- $11.50
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Eagle Equity Partners III, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as Soaring Eagle Acquisition Corp. or "Soaring Eagle") and Ginkgo Bioworks, Inc. ("Ginkgo"), among other things, each share of Soaring Eagle's Class B ordinary shares converted pursuant to the terms of such shares into shares of the Issuer's Class A common stock on a one-for-one basis. Simultaneously, pursuant to the Sponsor Support Agreement, dated as of May 11, 2021 (the "Sponsor Support Agreement") between the Reporting Person, Ginkgo, Soaring Eagle and certain other shareholders, the Reporting Person forfeited to the Issuer at no cost 11,534,052 shares of the Issuer's Class A common stock, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Footnote F2
The private placement warrants were acquired from the Issuer in connection with its initial public offering, the terms of which are described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-251661). Each private placement warrant is exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share, subject to certain adjustments. The private placement warrants are reported as acquired for purposes of Section 16 of the Exchange Act concurrently with the Closing, because they did not become derivative securities until such date based on the terms of their exercisability.
Footnote F3
Pursuant to the Sponsor Support Agreement, the Reporting Person forfeited to the Issuer at the Closing 10% of the private placement warrants it then held at no cost, which was exempted pursuant to Rule 16b-3(e) under the Exchange Act.